VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of an ...

Male reproductive health is receiving renewed attention in light of global concerns regarding declining semen quality, altered pubertal timing, and ...

The global DNA methylation market size was valued at US$ 1.9 Bn in 2025 and is projected to reach US$ 7.7 Bn by 2036, growing ...

Health Revealed” reveals how centralized healthcare systems prioritize profits over health, suppressing natural remedies and ...

Maternal prenatal stress related to natural and human-made disasters can lead to epigenetic modifications in offspring, ...

Volitionrx Ltd (NYSE:VNRX) shares rallied 18.5% on Thursday after the company unveiled encouraging performance data for its ...

Fox Chase will use Arima's 3D genomics technology as part of its diagnostic workflow for lymphoma and sarcoma.

Oryzon management will be available for one-on-one meetings during the conferences.

The collaboration with Fox Chase and its Cancer Epigenetics Institute will help physicians better identify genomic changes that traditional testing methods may miss, thus improving diagnosis and ...

The 2026 Middle Atlantic Regional Meeting (MARM) is accepting abstracts as of Jan. 5. The meeting will take place from May 17 ...

Agreement expands Cardio Diagnostics' global footprint and supports improved detection and management of coronary heart disease in India.